WallStreetZenWallStreetZen

NASDAQ: ATHA
Athira Pharma Inc Stock

Overview
ForecastEarningsDividendOwnership
$2.04-0.05 (-2.39%)
Updated Apr 23, 2024
ATHA Price
$2.04
Fair Value Price
$2.34
Market Cap
$78.19M
52 Week Low
$1.33
52 Week High
$4.30
P/E
-0.66x
P/B
0.6x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$117.67M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.23
Operating Cash Flow
-$101M
Beta
1.33
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A

ATHA Overview

Athira Pharma, Inc. is a late clinical-stage biopharmaceutical company developing small molecules to restore neuronal health and stop neurodegeneration brought on by Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease.Known as M3 Biotechnology, Inc. until 2019/04, the company was incorporated in 2011 and is headquartered in Bothell, WA.

Zen Score

–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ATHA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ATHA ($2.04) is undervalued by 12.85% relative to our estimate of its Fair Value price of $2.34 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ATHA ($2.04) is not significantly undervalued (12.85%) relative to our estimate of its Fair Value price of $2.34 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ATHA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ATHA due diligence checks available for Premium users.

Be the first to know about important ATHA news, forecast changes, insider trades & much more!

ATHA News

Valuation

ATHA fair value

Fair Value of ATHA stock based on Discounted Cash Flow (DCF)
Price
$2.04
Fair Value
$2.34
Undervalued by
12.85%
ATHA ($2.04) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ATHA ($2.04) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ATHA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ATHA price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.66x
Industry
16.46x
Market
41.92x

ATHA price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.6x
Industry
5.93x
ATHA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ATHA's financial health

Profit margin

Revenue
$0.0
Net Income
-$27.3M
Profit Margin
0%
ATHA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$160.2M
Liabilities
$30.1M
Debt to equity
0.23
ATHA's short-term assets ($154.73M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ATHA's short-term assets ($154.73M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ATHA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ATHA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$26.3M
Investing
$6.4M
Financing
$152.0k
ATHA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ATHA vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ATHA$78.19M-2.39%-0.66x0.60x
LVTX$78.34M+4.56%-1.75x1.41x
CGTX$78.00M+7.53%-2.33x3.19x
MRNS$78.69M-2.37%-0.55x4.69x
ENTX$78.77M+8.29%-7.16x7.58x
View Top Biotech Stocks

Athira Pharma Stock FAQ

What is Athira Pharma's quote symbol?

(NASDAQ: ATHA) Athira Pharma trades on the NASDAQ under the ticker symbol ATHA. Athira Pharma stock quotes can also be displayed as NASDAQ: ATHA.

If you're new to stock investing, here's how to buy Athira Pharma stock.

What is the 52 week high and low for Athira Pharma (NASDAQ: ATHA)?

(NASDAQ: ATHA) Athira Pharma's 52-week high was $4.30, and its 52-week low was $1.33. It is currently -52.54% from its 52-week high and 53.38% from its 52-week low.

How much is Athira Pharma stock worth today?

(NASDAQ: ATHA) Athira Pharma currently has 38,326,652 outstanding shares. With Athira Pharma stock trading at $2.04 per share, the total value of Athira Pharma stock (market capitalization) is $78.19M.

Athira Pharma stock was originally listed at a price of $17.11 in Sep 18, 2020. If you had invested in Athira Pharma stock at $17.11, your return over the last 3 years would have been -88.08%, for an annualized return of -50.78% (not including any dividends or dividend reinvestments).

How much is Athira Pharma's stock price per share?

(NASDAQ: ATHA) Athira Pharma stock price per share is $2.04 today (as of Apr 23, 2024).

What is Athira Pharma's Market Cap?

(NASDAQ: ATHA) Athira Pharma's market cap is $78.19M, as of Apr 24, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Athira Pharma's market cap is calculated by multiplying ATHA's current stock price of $2.04 by ATHA's total outstanding shares of 38,326,652.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.